A Director at Supernus Pharmaceuticals is Exercising Options


Today it was reported that a Director at Supernus Pharmaceuticals (SUPN), John Siebert, exercised options to buy 10,000 SUPN shares at $9.13 a share, for a total transaction value of $91.3K.

Following this transaction John Siebert’s holding in the company was increased by 27.98% to a total of $1.66 million.

See today’s analyst top recommended stocks >>

Based on Supernus Pharmaceuticals’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $116 million and quarterly net profit of $25.89 million. In comparison, last year the company earned revenue of $90.43 million and had a net profit of $26.35 million. SUPN’s market cap is $1.9B and the company has a P/E ratio of 17.68. Currently, Supernus Pharmaceuticals has an average volume of 286.1K.

Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $60.20, reflecting a 66.1% upside. Starting in January 2019, SUPN received 12 Buy ratings in a row. Five different firms, including B.Riley FBR and Cantor Fitzgerald, currently also have a Buy rating on the stock.

The insider sentiment on Supernus Pharmaceuticals has been positive according to 14 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

John Siebert’s trades have generated a 4.9% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts